Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
暂无分享,去创建一个
[1] Ji-Guang Wang,et al. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19 , 2020, Cardiovascular research.
[2] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.
[3] Tao Guo,et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.
[4] W. Gong,et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.
[5] D. Batlle,et al. Renin-Angiotensin System Blockers and the COVID-19 Pandemic , 2020, Hypertension.
[6] A. Verma,et al. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? , 2020, JAMA.
[7] G. Onder,et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.
[8] O. Pfister,et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? , 2020, European heart journal.
[9] Michael Roth,et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? , 2020, The Lancet Respiratory Medicine.
[10] M. Esler,et al. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? , 2020, Journal of hypertension.
[11] Xiang Xie,et al. COVID-19 and the cardiovascular system , 2020, Nature Reviews Cardiology.
[12] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[13] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[14] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[15] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[16] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[17] G. Corrao,et al. A new population-based risk stratification tool was developed and validated for predicting mortality, hospital admissions and healthcare costs. , 2019, Journal of clinical epidemiology.
[18] D. Pennell,et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.
[19] G. Mancia,et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension , 2018, European heart journal.
[20] Akshay S. Desai,et al. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impa , 2018, Circulation. Heart failure.
[21] M. Woodward,et al. Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes , 2016, Journal of hypertension.
[22] G. Mancia,et al. Adherence With Antihypertensive Drug Therapy and the Risk of Heart Failure in Clinical Practice , 2015, Hypertension.
[23] G. Mancia,et al. Generating evidence from computerized healthcare utilization databases. , 2015, Hypertension.
[24] M. Lai,et al. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients , 2012, Journal of hypertension.
[25] D. Batlle,et al. Pharmacologic modulation of ACE2 expression , 2008, Current hypertension reports.
[26] Martin Paul,et al. Physiology of local renin-angiotensin systems. , 2006, Physiological reviews.
[27] D. Diz,et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.
[28] John L. Sullivan,et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.